SCHEMBL788965

SCHEMBL788965

Fc1cc(F)c2[nH]cnc2c1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
PARP1 P09874 2/20 0.39
GPR84 Q9NQS5 1/20 0.37
IDO1 P14902 1/20 0.34
ALDH1A1 P00352 2/20 0.33
KDM4E B2RXH2 2/20 0.33
APEX1 P27695 1/20 0.33
RECQL P46063 1/20 0.33
BLM P54132 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
AR P10275 1/20 0.33
IP6K1 Q92551 2/20 0.33
IP6K3 Q96PC2 1/20 0.33
PDPK1 O15530 1/20 0.33
QPCT Q16769 2/20 0.32
DAO P14920 1/20 0.32
PRKCI P41743 1/20 0.31
MKNK1 Q9BUB5 1/20 0.31
RAD52 P43351 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL539264 0.79 PARP1 (0.41) MAPTPARP1ALDH1A1KDM4EAPEX1
SCHEMBL2411729 0.79 MAPT (0.39) MAPTPARP1ALDH1A1KDM4EAPEX1
SCHEMBL23227827 0.79 MAPT (0.47) MAPTPARP1IDO1ALDH1A1KDM4E
SCHEMBL2418293 0.75 MAPT (0.36) MAPTPARP1
SCHEMBL29171979 0.75 MAPT (0.36) MAPTPARP1
SCHEMBL19627520 0.75 MAPT (0.36) MAPTPARP1QPCT
SCHEMBL12320219 0.75 MAPT (0.36) MAPTPARP1
SCHEMBL15756185 0.75 MAPT (0.36) MAPTPARP1PDPK1
SCHEMBL29285163 0.75 PARP1 (0.41) MAPTPARP1ALDH1A1KDM4EIP6K1
SCHEMBL23718064 0.75 PARP1 (0.34) MAPTPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090491-A1 ENHANCED DELIVERY OF DISEASE-TARGETED NANOBODY-SIRNA CONJUGATES OHIO STATE INNOVATION FOUNDATION (US) 2026-04-30 WO disclosed
US-12559766-B2 Peanut with reduced allergen levels INGATEYGEN LLC (US) 2026-02-24 US disclosed
EP-3327140-B1 CAPTURE PROBES IMMOBILIZABLE VIA L-NUCLEOTIDE TAIL GEN PROBE INC (US) 2025-08-06 EP disclosed
US-20250136658-A1 ANTICONVULSANT AND NEUROPROTECTIVE AGENT THE UAB RESEARCH FOUNDATION 2025-05-01 US disclosed
US-12139706-B2 Method of nonspecific target capture of nucleic acids GEN-PROBE INCORPORATED (US) 2024-11-12 US disclosed
CN-110167955-B Bacterial inhibitors 梅哈里医学院 2024-04-02 CN disclosed
US-11920171-B1 Synthesis and oxidation of methane AUBURN UNIVERSITY (US) 2024-03-05 US disclosed
US-20230383335-A1 CLOSED NUCLEIC ACID STRUCTURES GEN-PROBE INCORPORATED 2023-11-30 US disclosed
US-20230340400-A1 MICROBIAL ESTER PRODUCTION AUBURN UNIVERSITY (US) 2023-10-26 US disclosed
US-11781176-B2 Method for blocking miRNA HUDSONALPHA INSTITUTE FOR BIOTECHNOLOGY (US) 2023-10-10 US disclosed
EP-2635703-A1 INTEGRATED CAPTURE AND AMPLIFICATION OF TARGET NUCLEIC ACID FOR SEQUENCING Gen-Probe Incorporated (US) 2013-09-11 EP disclosed
US-20130203123-A1 CLOSED NUCLEIC ACID STRUCTURES GEN-PROBE INCORPORATED (US) 2013-08-08 US disclosed
WO-2013116774-A1 ASYMMETRIC HAIRPIN TARGET CAPTURE OLIGOMERS GEN-PROBE INCORPORATED (US) 2013-08-08 WO disclosed
EP-2616555-A1 CAPTURE PROBES IMMOBILIZABLE VIA L-NUCLEOTIDE TAIL Gen-Probe Incorporated (US) 2013-07-24 EP disclosed
WO-2013036685-A1 CLOSED NUCLEIC ACID STRUCTURES GEN-PROBE INCORPORATED (US) 2013-03-14 WO disclosed
WO-2013036668-A1 CIRCULARIZED TEMPLATES FOR SEQUENCING GEN-PROBE INCORPORATED (US) 2013-03-14 WO disclosed
WO-2012061412-A1 INTEGRATED CAPTURE AND AMPLIFICATION OF TARGET NUCLEIC ACID FOR SEQUENCING GEN-PROBE INCORPORATED (US) 2012-05-10 WO disclosed
WO-2012037531-A1 CAPTURE PROBES IMMOBILIZABLE VIA L-NUCLEOTIDE TAIL GEN-PROBE INCORPORATED (US) 2012-03-22 WO disclosed
US-20080286775-A1 METHODS OF NONSPECIFIC TARGET CAPTURE OF NUCLEIC ACIDS GEN-PROBE INCORPORATED (US) 2008-11-20 US disclosed
US-20080267942-A1 BENZAZEPIN-2(1H)-ONE DERIVATIVES PFIZER LIMITED (GB) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559766-B2 Peanut with reduced allergen levels H1-2, CPA2, RNASEH1 MAPT 2600/4885PARP1 1119/4885GPR84 3895/4885
US-20080267942-A1 BENZAZEPIN-2(1H)-ONE DERIVATIVES ADRB2, ADRB1, ADRA2C MAPT 3299/4885PARP1 4275/4885GPR84 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.